These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 18024447)

  • 1. Regulatory and reimbursement challenges for molecular imaging.
    Hoffman JM; Gambhir SS; Kelloff GJ
    Radiology; 2007 Dec; 245(3):645-60. PubMed ID: 18024447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rational regulatory approach for positron emission tomography imaging probes: from "first in man" to NDA approval and reimbursement.
    Barrio JR; Marcus CS; Hung JC; Keppler JS
    Mol Imaging Biol; 2004; 6(6):361-7. PubMed ID: 15564146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Satisfying the requirements of the Food and Drug Administration and Centers for Medicare and Medicare Services.
    Smith JJ; Henderson JA
    J Am Coll Radiol; 2008 Mar; 5(3):189-92. PubMed ID: 18312966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular imaging: an overview and clinical applications.
    Rollo FD
    Radiol Manage; 2003; 25(3):28-32; quiz 33-5. PubMed ID: 12817419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The food and drug administration and molecular imaging agents: potential challenges and opportunities.
    Henderson JA; Alexander BC; Smith JJ
    J Am Coll Radiol; 2005 Oct; 2(10):833-40. PubMed ID: 17411943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diffusion of new imaging technologies: a molecular imaging prospective.
    Hillman BJ
    J Am Coll Radiol; 2006 Jan; 3(1):33-7. PubMed ID: 17412004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment and approval of medical devices used in diagnostic imaging in the United States.
    Johnson GC
    Isr J Med Sci; 1986; 22(7-8):505-18. PubMed ID: 3536797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular imaging and personalized medicine: an uncertain future.
    Nunn AD
    Cancer Biother Radiopharm; 2007 Dec; 22(6):722-39. PubMed ID: 18158763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rising costs of medical imaging spur debate.
    Rowan K
    J Natl Cancer Inst; 2008 Dec; 100(23):1665-7. PubMed ID: 19033570
    [No Abstract]   [Full Text] [Related]  

  • 12. Developing new molecular imaging probes for PET.
    Serdons K; Verbruggen A; Bormans GM
    Methods; 2009 Jun; 48(2):104-11. PubMed ID: 19318126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positron emission tomography: a financial and operational analysis.
    Conti PS; Keppler JS; Halls JM
    AJR Am J Roentgenol; 1994 Jun; 162(6):1279-86. PubMed ID: 8191981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Operation of a radiopharmacy for a clinical trial.
    Norenberg JP; Petry NA; Schwarz S
    Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using imaging biomarkers to accelerate drug development and clinical trials.
    Pien HH; Fischman AJ; Thrall JH; Sorensen AG
    Drug Discov Today; 2005 Feb; 10(4):259-66. PubMed ID: 15708744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roadmap for reform: outlook for imaging under accountable care.
    Lund IV; Hartman J
    Radiol Manage; 2011; 33(6):22-6; quiz 27-8. PubMed ID: 22235736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emergence of diagnostic imaging technologies in breast cancer: discovery, regulatory approval, reimbursement, and adoption in clinical guidelines.
    Gold LS; Klein G; Carr L; Kessler L; Sullivan SD
    Cancer Imaging; 2012 Jan; 12(1):13-24. PubMed ID: 22275726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New science-based endpoints to accelerate oncology drug development.
    Kelloff GJ; Sigman CC
    Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost of developing imaging agents for routine clinical use.
    Nunn AD
    Invest Radiol; 2006 Mar; 41(3):206-12. PubMed ID: 16481902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.